Clinical and genomic factors associated with seizures in meningiomas.

OBJECTIVE The association of seizures with meningiomas is poorly understood. Moreover, any relationship between seizures and the underlying meningioma genomic subgroup has not been studied. Herein, the authors report on their experience with identifying clinical and genomic factors associated with preoperative and postoperative seizure presentation in meningioma patients. METHODS Clinical and genomic sequencing data on 394 patients surgically treated for meningioma at Yale New Haven Hospital were reviewed. Correlations between clinical, histological, or genomic variables and the occurrence of preoperative and postoperative seizures were analyzed. Logistic regression models were developed for assessing multiple risk factors for pre- and postoperative seizures. Mediation analyses were also conducted to investigate the causal pathways between genomic subgroups and seizures. RESULTS Seventeen percent of the cohort had presented with preoperative seizures. In a univariate analysis, patients with preoperative seizures were more likely to have tumors with a somatic NF2 mutation (p = 0.020), WHO grade II or III tumor (p = 0.029), atypical histology (p = 0.004), edema (p < 0.001), brain invasion (p = 0.009), and worse progression-free survival (HR 2.68, 95% CI 1.30-5.50). In a multivariate analysis, edema (OR 3.11, 95% CI 1.46-6.65, p = 0.003) and atypical histology (OR 2.00, 95% CI 1.03-3.90, p = 0.041) were positive predictors of preoperative seizures, while genomic subgroup was not, such that the effect of an NF2 mutation was indirectly mediated through atypical histology and edema (p = 0.012). Seizure freedom was achieved in 83.3% of the cohort, and only 20.8% of the seizure-free patients, who were more likely to have undergone gross-total resection (p = 0.031), were able to discontinue antiepileptic drug use postoperatively. Preoperative seizures (OR 3.54, 95% CI 1.37-9.12, p = 0.009), recurrent tumors (OR 2.89, 95% CI 1.08-7.74, p = 0.035), and tumors requiring postoperative radiation (OR 2.82, 95% CI 1.09-7.33, p = 0.033) were significant predictors of postoperative seizures in a multivariate analysis. CONCLUSIONS Seizures are relatively common at meningioma presentation. While NF2-mutated tumors are significantly associated with preoperative seizures, the association appears to be mediated through edema and atypical histology. Patients who undergo radiation and/or have a recurrence are at risk for postoperative seizures, regardless of the extent of resection. Preoperative seizures may indeed portend a more potentially aggressive molecular entity and challenging clinical course with a higher risk of recurrence.

[1]  Mark W. Youngblood,et al.  Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. , 2020, Journal of neurosurgery.

[2]  N. Srikandarajah,et al.  Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes , 2019, Journal of Neuro-Oncology.

[3]  W. Stummer,et al.  Brain invasion and the risk of seizures in patients with meningioma. , 2019, Journal of neurosurgery.

[4]  F. Rosenow,et al.  Focused review on seizures caused by meningiomas , 2018, Epilepsy & Behavior.

[5]  A. Brodbelt,et al.  Postoperative seizures in meningioma patients: improving patient selection for antiepileptic drug therapy , 2018, Journal of Neuro-Oncology.

[6]  C. Mawrin,et al.  Brain invasion in meningiomas—clinical considerations and impact of neuropathological evaluation: a systematic review , 2017, Neuro-oncology.

[7]  M. Sanson,et al.  SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas , 2017, Neuro-oncology.

[8]  Mark W. Youngblood,et al.  Integrated genomic analyses of de novo pathways underlying atypical meningiomas , 2017, Nature Communications.

[9]  C. Meisner,et al.  Risk Factors of Preoperative and Early Postoperative Seizures in Patients with Meningioma: A Retrospective Single-Center Cohort Study. , 2017, World neurosurgery.

[10]  A. Nanda,et al.  Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma. , 2017, Journal of neurosurgery.

[11]  W. Stummer,et al.  Brain Invasion in Meningiomas: Incidence and Correlations with Clinical Variables and Prognosis. , 2016, World neurosurgery.

[12]  Mark W. Youngblood,et al.  Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas , 2016, Nature Genetics.

[13]  M. Weller,et al.  Predicting outcome of epilepsy after meningioma resection. , 2016, Neuro-oncology.

[14]  J. Schramm,et al.  The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. , 2016, Journal of neurosurgery.

[15]  T. Tomson,et al.  Intracranial meningiomas and seizures: a review of the literature , 2015, Acta Neurochirurgica.

[16]  Yun-Bao Guo,et al.  Clinical multifactorial analysis of early postoperative seizures in elderly patients following meningioma resection. , 2015, Molecular and clinical oncology.

[17]  Thomas Backer-Grøndahl,et al.  Immunohistochemical characterization of brain-invasive meningiomas. , 2014, International journal of clinical and experimental pathology.

[18]  C. Vecht,et al.  Seizure prognosis in brain tumors: new insights and evidence-based management. , 2014, The oncologist.

[19]  Junming Zhu,et al.  Early and late postoperative seizure outcome in 97 patients with supratentorial meningioma and preoperative seizures: a retrospective study , 2013, Journal of Neuro-Oncology.

[20]  Murim Choi,et al.  Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO , 2013, Science.

[21]  G. Gallia,et al.  Seizure control for patients undergoing meningioma surgery. , 2013, World neurosurgery.

[22]  D. Eccles,et al.  Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas , 2013, Nature Genetics.

[23]  Christian Hartmann,et al.  IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom , 2012, Seizure.

[24]  P. Wen,et al.  Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas , 2012, Journal of Neuro-Oncology.

[25]  E. Chang,et al.  Postoperative seizures following the resection of convexity meningiomas: are prophylactic anticonvulsants indicated? Clinical article. , 2011, Journal of neurosurgery.

[26]  A. Kyritsis,et al.  Epilepsy in the cancer patient , 2011, Cancer Chemotherapy and Pharmacology.

[27]  R. Soffietti,et al.  Epilepsy and brain tumors , 2010, Current opinion in oncology.

[28]  C. Vecht,et al.  Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management , 2007, The Lancet Neurology.

[29]  L. D.,et al.  Brain tumors , 2005, Psychiatric Quarterly.

[30]  M. Lyons,et al.  Seizure prophylaxis in patients with brain tumors: a meta-analysis. , 2004, Mayo Clinic proceedings.

[31]  Martin Klein,et al.  Cognitive deficits in adult patients with brain tumours , 2004, The Lancet Neurology.

[32]  N. Hashimoto,et al.  The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. , 2004, Surgical neurology.

[33]  Christian E Elger,et al.  The Spectrum of Long‐term Epilepsy–associated Tumors: Long‐term Seizure and Tumor Outcome and Neurosurgical Aspects , 2003, Epilepsia.

[34]  S. Howng,et al.  Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors , 1999, Epilepsy Research.

[35]  S. Kameyama,et al.  Peritumoral edema and seizure in patients with cerebral convexity and parasagittal meningiomas. , 1996, Neurologia medico-chirurgica.

[36]  B. Chozick,et al.  Incidence of seizures after surgery for supratentorial meningiomas: a modern analysis. , 1996, Journal of neurosurgery.